



Stephen Joel Coons, PhD  
Executive Director, PRO Consortium  
Critical Path Institute  
1730 E. River Road  
Tucson, AZ 85718  
Email: [SJCoons@c-path.org](mailto:SJCoons@c-path.org)

April 4, 2018

Dear Dr. Coons,

On behalf on the qualification review team, in reference to your qualification review package submitted March 30, 2017 for Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), we have qualified the NSCLC-SAQ for exploratory use. Attached you will find the qualification statement for the NSCLC-SAQ, which describes the NSCLC-SAQ and its qualified context of use.

If you have any questions, please contact the COA Staff via email at [coaddtqualification@fda.hhs.gov](mailto:coaddtqualification@fda.hhs.gov). Please reference DDT #000009.

Sincerely,

Elektra J.

Papadopoulos -S

Digitally signed by Elektra J. Papadopoulos -S  
DN: c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People,  
0.9.2342.19200300.100.1.1=1300170743,  
cn=Elektra J. Papadopoulos -S  
Date: 2018.04.04 16:47:10 -04'00'

Elektra Papadopoulos, MD, MPH  
Associate Director  
Clinical Outcome Assessments Staff  
Office of New Drugs  
Center for Drug Evaluation and Research

Patricia

Keegan -S

Digitally signed by Patricia Keegan -S DN:  
c=US, o=U.S. Government, ou=HHS,  
ou=FDA, ou=People,  
0.9.2342.19200300.100.1.1=1300064118,  
cn=Patricia Keegan -S  
Date: 2018.04.10 12:48:40 -04'00'

Patricia Keegan, MD  
Director  
Division of Oncology Products 2 (DOP2)  
Office of New Drugs  
Center for Drug Evaluation and Research